Levamisole Boosts Hepatitis B Vaccine Response in Hemodialysis Patients
Author Information
Author(s): Argani Hassan, Akhtarishojaie Ebrahim
Primary Institution: Shahid Beheshti University of Medical Sciences, Tehran, Iran
Hypothesis
Does Levamisole enhance the immune response to hepatitis B vaccination in chronic hemodialysis patients?
Conclusion
Levamisole significantly improves the immune response to hepatitis B vaccination in hemodialysis patients, especially when administered via the intradermal route.
Supporting Evidence
- The response rate to routine IM vaccination was low at 60%, but increased to 70% with ID route.
- Levamisole raised the response rate to 90% in both IM and ID groups.
- Antibody titers were maintained better in the Levamisole groups after six months.
Takeaway
This study shows that giving a medicine called Levamisole with a hepatitis B vaccine helps people on dialysis make more antibodies to fight the virus.
Methodology
44 chronic hemodialysis patients were divided into four groups to receive different vaccination routes and Levamisole, with antibody titers measured after one and six months.
Potential Biases
Potential selection bias due to exclusion criteria and the non-randomized nature of group assignments.
Limitations
The study had a small sample size and was limited to a single center.
Participant Demographics
Mean age 45 years, 25 males and 19 females, with various underlying diseases.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website